TL;DR
This study reveals that the tau PET tracer 18F-THK5351 binds to monoamine oxidase B (MAO-B) in the brain, not just tau pathology. This off-target binding confounds imaging results, particularly in early Alzheimer's disease, and necessitates re-evaluation of how 18F-THK5351 PET scans are interpreted and utilized.
What Problem Does This Paper Address?
Positron Emission Tomography (PET) tracers are crucial for diagnosing and monitoring neurodegenerative diseases like Alzheimer's disease (AD) by visualizing specific pathological hallmarks. 18F-THK5351 is a promising PET tracer designed to detect paired helical filaments (PHF), a key component of tau pathology in AD. However, researchers observed that 18F-THK5351 showed high uptake in brain regions that are known to have very little tau pathology but are rich in monoamine oxidase B (MAO-B), an enzyme involved in neurotransmitter metabolism. This discrepancy raised a critical question: is 18F-THK5351 truly specific for tau, or is its signal being influenced by MAO-B? This paper aims to investigate this by testing the hypothesis that MAO-B inhibition would reduce 18F-THK5351 uptake.
Methods
The researchers employed a multi-pronged approach:
- In Vivo PET Imaging: Eight participants (with mild cognitive impairment, AD, or progressive supranuclear palsy) underwent two PET scans. The first was a baseline scan using 18F-THK5351. A week later, they received a single 10mg oral dose of selegiline, an MAO-B inhibitor, and then underwent a second 18F-THK5351 PET scan one hour later. A subset of participants had a third scan several weeks later to assess the duration of the effect. Standardized Uptake Value (SUV) was calculated to quantify tracer uptake.
- Autoradiography: To complement the in vivo findings, postmortem human brain tissue from AD patients and healthy controls was used. This tissue was incubated with 18F-THK5351 in the presence of varying concentrations of selegiline (or its active metabolite, R-(-)-deprenyl hydrochloride) to directly assess the competition for binding sites.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- MAO-B is a significant off-target for 18F-THK5351: The most crucial finding is the clear evidence that 18F-THK5351 binds to MAO-B. This means that PET scans using this tracer are not solely reflecting tau pathology but are also capturing MAO-B activity.
- Confounding effect in early AD: The high MAO-B availability in brain regions like the basal ganglia and thalamus, which have low tau burden, means that 18F-THK5351 uptake in these areas is likely dominated by MAO-B binding, especially in the early stages of AD when tau pathology is less widespread.
- Implications for reference regions: The widespread and heterogeneous distribution of MAO-B across the brain, including in regions often used as reference for PET imaging (like the cerebellum), complicates the use of standardized uptake value ratios (SUVR) for quantifying tau pathology.
- Long-lasting MAO-B inhibition: The observed reduction in 18F-THK5351 uptake persisted for weeks after a single selegiline dose, aligning with the known long half-life of MAO-B inhibition.
Key Results
- Significant uptake reduction: After selegiline administration, regional 18F-THK5351 SUVs decreased by an average of 36.7% to 51.8%. The greatest reductions were seen in the thalamus (51.8%) and basal ganglia (51.4%), regions known for high MAO-B and low tau.
- Cerebellar uptake also affected: Even the cerebellar cortex, often used as a reference region, showed a significant reduction (41.6%) in 18F-THK5351 SUVs after selegiline.
- Autoradiography confirms binding: Postmortem studies showed that R-(-)-deprenyl hydrochloride dose-dependently reduced 18F-THK5351 binding, with a greater effect in the striatum (high MAO-B, low tau) compared to the prefrontal cortex and hippocampus (both MAO-B and tau).
Limitations and Future Work
- Methodological Limitations: The study used SUV measurements from a specific time window rather than full dynamic scans with arterial input functions, which could introduce variability. The potential effect of acute selegiline on cerebral blood flow was also noted as a possible confounder.
- Future Directions: The authors emphasize the need for future research to develop methods to correct for MAO-B bias in 18F-THK5351 imaging. They also suggest that experiments should be designed to account for the age-related increases in both MAO-B and tau binding, and that the confounding effect of MAO-B availability in patients with high tau loads needs further investigation. The findings also highlight the importance of considering individual differences in selegiline metabolism and potential interactions with other substances.
Summary updated